Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Ambry Genetics Launches FFPE Somatic Variant Profiling Services

Published: Monday, April 08, 2013
Last Updated: Monday, April 08, 2013
Bookmark and Share
Ambry Genetics announced today that they have launched a somatic variant detection service, developed in collaboration with Illumina.

This service complements Ambry’s extensive menu of next-generation sequencing services and portfolio of diagnostic genetic testing panels for hereditary cancers.

Ambry Genetics has offered next-generation sequencing services since 2007 and has been at the forefront of establishing the technology as a diagnostic tool. Ambry was the first to launch a commercial diagnostic test utilizing next-generation sequencing with their 81 gene XLID panel, as well as the first to offer clinical exome sequencing. Leveraging years of experience, Ambry has developed a somatic cancer panel that can detect the lowest level allele frequency with the highest level of specificity available today.

“Utilizing a novel target enrichment strategy, we are able to detect below 3% minor allele frequency with very high confidence,” said Dr. Aaron Elliott, Director of R&D at Ambry Genetics. “We have optimized every step of the process from QC to bioinformatics to virtually eliminate false positives which are a common problem for FFPE samples in current panels.”

This offering is focused on clinically actionable mutations implicated in solid tumors with a focus on lung, colon, melanoma, gastric and ovarian cancers. The assay covers relevant hotspot regions of 26 genes, including deep sequencing of several genes such as TP53.

“Expanding into somatic mutation detection is a key step to grow our business,” said Ardy Arianpour, Vice President of Business Development at Ambry Genetics. “We have had several top pharmaceutical clients test the product and are extremely happy with the data, we look to further develop the offering and move it into our clinical diagnostics menu this year.”

“Our understanding of cancer is rapidly evolving through a better understanding of genomics. Partnering with leaders in next-generation sequencing services enables us to build better targeted sequencing solutions that fit the needs of service providers,” said Greg Heath, Senior Vice President and General Manager of Illumina’s Diagnostics business. “Bringing services to the clinical research market will help to further evolve our understanding of cancer and ultimately lead to better diagnostic tools.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Largest Disease-Specific Public Database of Sequenced Human Genomes
Pledges sizeable investment to collect, sequence, and share critical data to unlock true potential of the human genome, breaking the hoarding data mold that hinders medical progress.
Tuesday, March 15, 2016
Ambry Genetics Reports Results from Clinical Diagnostic Exome™ Testing of Three Patients
Three individuals suffering from symptoms for which the cause could not be identified were successfully diagnosed. The findings are believed to mark the first of their kind in industry, with additional information to be released in the coming weeks.
Monday, January 23, 2012
Ambry Genetics Launches Illumina HiSeq 2000 Next Generation Sequencing Services
Ambry Genetics has been an early adapter of Illumina sequencing systems since 2007 and has extensive experience as a Certified Service Provider.
Friday, December 10, 2010
Ambry Genetics Acquires Illumina Hiseq 2000 and First 510(K) Approved Beadxpress®
The acquisition of Illumina systems allows Ambry to expand its sequencing and genotyping capabilities.
Thursday, August 26, 2010
Ambry Genetics and RainDance Technologies Announce Partnership for Diagnostics and Genomics Services
Ambry Genetics and RainDance Technologies today jointly announced their partnership utilizing the RDT 1000 for sequence enrichment and resequencing validation.
Wednesday, March 17, 2010
Ambry Genetics Announces Launch of their StemArray™ Product and Services for High Resolution Characterization of Human Stem Cells
Ambry Genetics today introduces their new StemArray™ product and services utilizing aCGH technology to cover the entire genome.
Monday, January 25, 2010
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Grant Supports Project To Develop Simple Test To Screen For Cervical Cancer
UCLA Engineering announces funding from Bill and Melinda Gates Foundation.
Injecting New Life into Old Antibiotics
A new fully synthetic way to make a class of antibiotics called macrolides from simple building blocks is set to open up a new front in the fight against antimicrobial drug resistance.
Insight into Bacterial Resilience and Antibiotic Targets
Variant of CRISPR technology paired with computerized imaging reveals essential gene networks in bacteria.
Advancing Protein Visualization
Cryo-EM methods can determine structures of small proteins bound to potential drug candidates.
Alzheimer’s Protein Serves as Natural Antibiotic
Alzheimer's-associated amyloid plaques may be part of natural process to trap microbes, findings suggest new therapeutic strategies.
Slime Mold Reveals Clues to Immune Cells’ Directional Abilities
Study from UC San Diego identifies a protein involved in the directional ability of a slime mold.
How Do You Kill A Malaria Parasite?
Drexel University scientists have discovered an unusual mechanism for how two new antimalarial drugs operate: They give the parasite’s skin a boost in cholesterol, making it unable to traverse the narrow labyrinths of the human bloodstream. The drugs also seem to trick the parasite into reproducing prematurely.
Illuminating Hidden Gene Regulators
New super-resolution technique visualizes important role of short-lived enzyme clusters.
Supressing Intenstinal Analphylaxis in Peanut Allergy
Study from National Jewish Health shows that blockade of histamine receptors suppresses intestinal anaphylaxis in peanut allergy.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!